Cullinan Therapeutics

Cullinan makes new medicines for cancer and autoimmune diseases.

Its products help the body's immune system attack sick cells.

These medicines aim to be easy for patients to take.

New Medicines for Tough Diseases

• Autoimmune Programs: Treatments like CLN-978 and velinotamig use proteins called T cell engagers to find and remove harmful B cells in patients with lupus or arthritis.
• Targeted Oncology: Therapies such as CLN-049 focus on specific proteins found on the surface of leukemia cells to treat blood cancer.
• Oral Lung Cancer Treatment: An irreversible inhibitor called zipalertinib is designed to target specific genetic mutations in lung cancer while sparing healthy cells.

Partnerships and Fresh Starts

• Licensed velinotamig from Chongqing Genrix Biopharmaceutical in June 2025 to develop the treatment outside of Greater China.
• Completed a rolling submission for accelerated approval of zipalertinib in February 2026 for certain lung cancer patients.
• Ended development of CLN-619, CLN-617, and CLN-418 in 2024 and 2025 to concentrate resources on higher-priority programs.
• Partnered with Adimab to use their technology for discovering and optimizing the antibodies used in the company's leading programs.

Why Cullinan Stands Out

Cullinan uses a specialized platform to create bispecific T cell engagers, which are molecules that bridge the gap between immune cells and diseased cells. This approach allows for off-the-shelf medicines that patients can receive via a simple injection rather than through complex hospital manufacturing processes.

Counting the Costs

• Net loss reached $50.7 million in Q4 2025, which was a 6.4% worsening compared to the previous year.
• Operating cash flow reached negative $38.1 million in Q4 2025, worsening by 4% year-over-year.
• Operating income was negative $55.3 million in Q4 2025, representing a 0.4% decline from the prior period.
• The company's market capitalization stood at $612.7 million in Q4 2025, down 14.1% from the previous year.

The Path Forward

Cullinan has successfully transitioned from a pure oncology focus to a broader biopharmaceutical model targeting both cancer and autoimmune conditions. By streamlining its pipeline and securing key licenses, the company is prioritizing its most advanced clinical-stage candidates for regulatory review.